my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-11-2006: Joost Helsen has been appointed General Manager of Nobilon, the human vaccines business of Organon BioSciences. Nobilon is a key strategic initiative, founded in 2002, that bridges Intervet's expertise in vaccine development with Organon's ability to register and market human health care products.
Joost Helsen (48) joined Organon in 1985. After having served in various financial functions within Organon and Akzo Nobel, he joined Intervet in 1995 as controller. Mr. Helsen will have a pivotal role in the execution of the overall Organon BioSciences biotechnology strategy. Since 2003, Mr. Helsen has been responsible for manufacturing and logistics at Intervet International and has been a Member of the Executive Committee of Intervet.
Nobilon intends to become a fully integrated biotechnology company encompassing research, development, registration, production and commercialization of selected vaccines. The cost efficient production of vaccines through cell culture shall serve as a platform for Nobilon to build a strong position in the areas of influenza and other respiratory vaccine development. The Nobilon facility received European approval last year to manufacture both animal and human vaccines.
Watchlist
This is where you can add this news to your personal favourites
Akzo Nobel N.V. has completed the sale of Organon BioSciences N.V. to Schering-Plough Corporation for EUR 11 billion. Confirmation of the completion of the transaction comes after Schering-Plough received all the necessary approvals, including clearance from the U.S. Federal Trade Commissio ... more
Organon, the human healthcare business unit of Akzo Nobel, announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to the ... more
European expert consortium combines forces to develop a novel pandemic influenza vaccine
A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund t ... more
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core the ... more
Nobilon advances intranasal seasonal influenza vaccine into proof of concept study
Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use. “We are encouraged by the continuation of the clini ... more
Nobilon advances first vaccine into human trials
Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal ... more
European expert consortium combines forces to develop a novel pandemic influenza vaccine
A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund t ... more
Nobilon International BV, part of Organon, was founded in 2003. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines. Nobilon draws on expertise from its related businesses Organon, In ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
